AMSBIO offers a wide range of small molecules to provide scientists with targeted tools to direct cell fates, making them crucial in areas including regenerative medicine and cancer research.
Small molecules are cell-permeable organic compounds with low molecular weights, which are chemically produced, in contrast to larger molecules such as proteins which are often produced via biological means. Small molecules are crucial components of an affordable cell culture toolkit that can be used to maintain, reprogram, and differentiate cells.
Typically, small molecules are cost-effective:…
Capivasertib alongside hormone therapy doubles time before advanced breast cancer progresses
Combination set to become new treatment option for patients with advanced forms of most common type of breast cancer
Inhibitor of cancer-driving protein AKT shows broad benefits in patients with ER positive, HER2 negative breast cancer
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.
The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people…
Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design
Tokyo, Japan and Cambridge, UK, 8 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the…
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and potentially offer improved assay sensitivity and selectivity over antibodies.
Optimer binders are oligonucleotide-based affinity ligands generated through the in vitro Optimer platform, which can be used as antibody alternatives. They offer benefits of ethical compliance with no use of animals in discovery, development of manufacture, the…
Click here to view the November edition of The Meeting Place
Welcome to the Autumn edition of BioBrief, our quarterly newsletter providing essential updates and analysis for those working in the life sciences sector.
In this edition you will find:
> A videocast on the recent decision of the Patents Court to uphold the validity of an important Astellas patent protecting their blockbuster product Mirabegron
> An article on how the UK is moving into the fast lane for biosimilar regulatory approvals
> An article outlining the new UK immigration routes in 2022
> Our newly developed SCC toolkit which will help you understand whether your…
AMSBIO has published an informative handbook for scientists who need to preserve or archive organoids in a research lab.
The handbook brings together published paper citations, quotes and data from leading international research groups who are using the CELLBANKER® range of products to cryopreserve their organoids simply and safely. In addition, the handbook includes best practice protocols plus information making it easier to understand the process of freezing organoids and to choose the optimum cryopreservation media for your application.
Proven capable of recreating aspects of organ…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES
Clinical Trial Application approved
EU Phase I clinical trial expected to commence in December 2022
Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting,…
The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio
Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the Japan Patent Office has granted a patent (JP7145849) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278. The same patent has also been granted in South Korea.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented…